Roche, A*STAR Collaborate On Developing Anti-Cancer Novel Antibodies
This article was originally published in PharmAsia News
Executive Summary
Roche and Singapore's A*STAR institute have agreed to joint development of a cancer treatment that relies on monoclonal antibodies to target cells for destruction.